1. Home
  2. Stocks
  3. Infinium Share Price

Infinium Pharmachem Share Price

Pharmaceuticals Small Cap

₹321.25 -4.75 (-1.46%)

05 Nov, 2024 16:50

SIP TrendupStart SIP in INFINIUM

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹318
  • High
  • ₹328
  • 52 Week Low
  • ₹178
  • 52 Week High
  • ₹393
  • Open Price₹326
  • Previous Close₹326
  • Volume4,000

Investment Returns

  • Over 1 Month -12.59%
  • Over 3 Month + 75.5%
  • Over 6 Month + 46.36%
  • Over 1 Year + 25.66%
SIP Lightning

Smart Investing Starts Here Start SIP with Infinium Pharmachem for Steady Growth!

Infinium Pharmachem Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • PEG Ratio
  • Market Cap Cr
  • 447
  • P/B Ratio
  • 7.4
  • Average True Range
  • 12.32
  • EPS
  • 8
  • Dividend Yield
  • 0
  • MACD Signal
  • 10.41
  • RSI
  • 55.27
  • MFI
  • 24.89

Infinium Pharmachem Financial

IndicatorMar 24Mar 23
Revenue From Operations [Gross]122.36101.31
Revenue From Operations [Net]122.36101.31
Total Operating Revenues122.36101.31
Total Revenue123.98102.65
Total Expenses109.1290.38
Profit/Loss Before Tax14.8612.26
Profit/Loss For The Period11.099.15
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity-14.977.35
Net Cash Used In Investing Activity-3.29-2.58
Net Cash Used in Finance Activity23.19-3.00
Net Inc/Dec In Cash And Equivalent4.921.77
Cash And Equivalent End Of Year8.243.32
IndicatorMar 24Mar 23
Total Share Capital13.925.08
Total Non-Current Liabilities5.507.63
Total Current Liabilities14.4931.09
Total Capital And Liabilities77.7460.42
Total Non-Current Assets17.5116.41
Total Current Assets60.2344.00
Total Assets77.7460.42
Indicator20242023
EBIT Margin (%)13.5915.06
Return On Capital Employed (%)26.2952.03
Return On Equity (%)19.2042.16
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)41.5021.34
IndicatorMar 24Mar 23
Revenue From Operations [Gross]135.66114.22
Revenue From Operations [Net]135.66114.22
Total Operating Revenues135.66114.22
Total Revenue137.20115.58
Total Expenses121.99102.62
Profit/Loss Before Tax15.2112.95
Profit/Loss For The Period11.509.82
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity-13.048.59
Net Cash Used In Investing Activity-3.79-4.96
Net Cash Used in Finance Activity22.77-3.10
Net Inc/Dec In Cash And Equivalent5.930.53
Cash And Equivalent End Of Year11.915.98
IndicatorMar 24Mar 23
Total Share Capital13.925.08
Total Non-Current Liabilities7.8910.06
Total Current Liabilities17.3336.77
Total Capital And Liabilities85.4570.61
Total Non-Current Assets20.4419.30
Total Current Assets65.0151.31
Total Assets85.4570.61
Indicator20242023
EBIT Margin (%)12.8214.05
Return On Capital Employed (%)25.5447.44
Return On Equity (%)19.2242.06
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)43.2823.39

Infinium Pharmachem Technicals

EMA & SMA

Current Price
₹321.25
-4.75 (-1.46%)
pointer
  • stock-down_img
  • Bullish Moving Average 9
  • stock-up_img
  • Bearish Moving Average 7
  • 20 Day
  • ₹322.04
  • 50 Day
  • ₹295.51
  • 100 Day
  • ₹268.09
  • 200 Day
  • ₹244.89

Resistance and Support

325.33 Pivot Speed
  • R3 328.67
  • R2 327.33
  • R1 326.67
  • S1 324.67
  • S2 323.33
  • S3 322.67

Is Infinium Pharmachem Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Infinium Pharmachem Ltd has an operating revenue of Rs. 419.53 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 11% is healthy, ROE of 19% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 16% and 36% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 95 which is a GREAT score indicating consistency in earnings, a RS Rating of 81 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 30 indicates it belongs to a strong industry group of Comml Svcs-Healthcare and a Master Score of C is fair but needs to improve. Overall, the stock has great fundamentals and technical strength to stay in momentum. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Infinium Pharmachem Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-05-29 Audited Results
2023-10-27 Quarterly Results
2023-08-02 Bonus issue
2023-05-17 Audited Results
Date Purpose Remarks
2023-09-13 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.

Infinium Pharmachem F&O

Infinium Pharmachem Shareholding Pattern

73.05%
23.97%
2.98%
  • NSE Symbol
  • INFINIUM
  • BSE Symbol
  • Managing Director
  • Mr. Sanjaykumar Viththalbhai Patel
  • ISIN
  • INE0MRE01011

Infinium Pharmachem FAQs

Infinium Pharmachem share price is ₹321 As on 05 November, 2024 | 16:36

The Market Cap of Infinium Pharmachem is ₹447.1 Cr As on 05 November, 2024 | 16:36

The P/E ratio of Infinium Pharmachem is As on 05 November, 2024 | 16:36

The PB ratio of Infinium Pharmachem is 7.4 As on 05 November, 2024 | 16:36

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.